Exelixis Inc Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
Exelixis Inc (EXEL) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $22.98 per share for the 12-month period ending 2020-01-03, per its 10-K filed 2020-02-25.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2020-02-25
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2019-03-29 was $22.12.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2015-03-31 was $6.06, a 21.81% decline year-over-year.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2014-03-31 was $7.75.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2020 was $22.98, a 11.34% increase from fiscal 2018.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2018 was $20.64, a 108.27% increase from fiscal 2017.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2017 was $9.91, a 5.53% decline from fiscal 2016.
- Exelixis Inc share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2016 was $10.49, a 47.33% increase from fiscal 2015.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2020-01-03 | $22.98 10-K · filed 2020-02-25 | |||
| 2019-09-27 | $23.41 10-Q · filed 2019-10-30 | |||
| 2019-06-28 | $22.89 10-Q · filed 2019-07-31 | |||
| 2019-03-29 | $22.12 10-Q · filed 2019-05-01 | |||
| 2018-12-28 | $20.64 10-K · filed 2019-02-22 | |||
| 2018-09-28 | $18.62 10-Q · filed 2018-11-01 | |||
| 2017-12-29 | $9.91 10-K · filed 2018-02-26 | |||
| 2016-12-31 | $10.49 10-K · filed 2017-02-27 | |||
| 2016-09-30 | $10.49 10-Q · filed 2016-11-03 | |||
| 2016-06-30 | $10.89 10-Q · filed 2016-08-03 | |||
| 2015-12-31 | $7.12 10-K · filed 2016-02-29 | |||
| 2015-09-30 | $6.52 10-Q · filed 2015-11-10 | |||
| 2015-06-30 | $6.08 10-Q · filed 2015-08-11 | |||
| 2015-03-31 | $6.06 10-Q · filed 2015-04-30 | |||
| 2014-12-31 | $8.06 10-K · filed 2015-03-02 | |||
| 2014-09-30 | $7.31 10-Q · filed 2014-11-04 | |||
| 2014-06-30 | $7.85 10-Q · filed 2014-07-31 | |||
| 2014-03-31 | $7.75 10-Q · filed 2014-05-01 | |||
| 2013-12-31 | $6.45 10-K · filed 2015-03-02 | |||
| 2012-12-31 | $7.54 10-K · filed 2015-03-02 | |||
| 2011-12-31 | $12.13 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |